News
Voices of Hodgkin’s Blog
Voices of Hodgkin’s Blog

After Cancer, a Complex Aftermath for Survivors

This article features our very own Dr. Samantha Siegel, a member of the Board at Hodgkins International and Hodgkin lymphoma survivor, who shares her personal experience navigating the lasting effects of cancer treatment, including nerve pain, cognitive difficulties, and reduced physical endurance. Her story reflects the experiences of many survivors who find that life after cancer brings challenges that are often overlooked.

Findings from 2026 Survivor Survey

Surviving cancer as a child or teen brings lifelong needs that our healthcare and policy systems do not always meet. The 2026 survey found survivors navigating persistent fears of recurrence and late effects, gaps in long-term and adult care, financial and access barriers, and an ongoing need for better information and support. The message is clear: progress against childhood cancer must be measured not only by how many children survive but by how well survivors are able to live and thrive for decades to come.

Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors

Many long-term survivors were diagnosed before genetic testing was commonly offered, but that does not mean it is too late to benefit from it. This article highlights a study showing that some survivors may still carry inherited variants that could affect their future screening, follow-up care, and even family members’ health decisions. It is an encouraging reminder that new information can still make a meaningful difference, even years after treatment.

Older Childhood Cancer Survivors Still Face Serious Long-Term Risks

For many long-term survivors, late effects are not new, but it is encouraging to see the medical literature continuing to validate just how serious and long-lasting they can be. This important article reports that survivors of childhood cancer age 50 and older still face higher risks of second cancers, serious chronic health problems, frailty, and premature death, especially those who were treated with radiation. It is a powerful reminder that these health issues are real, treatment-related, and deserving of lifelong follow-up and screening.

Clinical Trial Update: The COMMENCE Study 10-Year Durability Results Released at AATS

For many survivors who need a valve replacement, one of the biggest questions is how long the new valve will last. This recent HeartValveSurgery.com update shares encouraging 10-year results from the COMMENCE trial, suggesting strong durability for the INSPIRIS RESILIA tissue valve and low rates of repeat surgery. It is hopeful news for survivors looking for reassurance about long-term outcomes.

Spotlight on the BETER Clinic: Leading the Way in Survivorship Care

By Sophia Smith, PhD, Chair of Hodgkin’s International

Sophia with Dr. Flora van Leeuwen, a senior epidemiologist and key leader of the BETER program, and an international leader in Hodgkin lymphoma survivorship research, at the Netherlands Cancer Institute.

During my sabbatical at the Netherlands Cancer Institute (NKI), I have been working closely with investigators affiliated with the BETER program, one of the world’s most comprehensive survivorship initiatives for people treated for Hodgkin lymphoma (HL). BETER (short for Better care after HL) was established to systematically identify, prevent, and manage the long-term and late adverse effects of HL treatment using a risk-based, personalized follow-up approach. Embedded within BETER is the INSIGHT study, a large-scale survivorship cohort that is generating rich data on late effects and patient-reported outcomes.

My role as a visiting scholar at NKI has focused on analyzing INSIGHT data. To date, I have drafted a first manuscript reporting survivors’ knowledge of late adverse effects, and I have begun work on a second manuscript examining how worry about late adverse effects can impact quality of life among HL survivors. This work is closely aligned with the foundational research led by Dr. Flora van Leeuwen, one of the foundational scientific leaders of the BETER program and an internationally respected survivorship researcher, as well as her long-time collaboration with Dr. Kevin Oeffinger, a global leader in cancer survivorship and a valued colleague of mine. Dr. Oeffinger helped facilitate my sabbatical at NKI, making this cross-national collaboration possible. Together, this work highlights how data embedded within clinical survivorship programs like BETER can directly inform research, advocacy, and improved long-term care for survivors, a priority that strongly resonates with Hodgkin International’s mission.

Learn more about the BETER program at: https://www.beternahodgkin.nl/

The Unbreakable Spirit

It can be so validating to hear another survivor’s story. In Coping Magazine, Nicole shares her experience with two cancer diagnoses, fertility struggles, treatment, and what she has learned from cancer.